Evidence map›Paper›PMID 34056545›Full record

ArticleSN applied sciences2021

Identification of degradation impurity of TGR5 receptor agonist-ZY12201 by LC-MS technique during force degradation study.

Chandrakant Sojitra, Chintan Dholakia, Padmaja Sudhakar, Kumar K Singh, Sameer Agarwal

Open access · goldAbstract read
In one paragraph

Article in SN applied sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Chandrakant SojitraAPI Division, Cadila Healthcare Limited, Sarkhej-Bavla N.H. No. 8 A, Changodar, Ahmedabad, 382 210 India.
Chintan DholakiaAPI Division, Cadila Healthcare Limited, Sarkhej-Bavla N.H. No. 8 A, Changodar, Ahmedabad, 382 210 India.
Padmaja SudhakarDepartment of Chemistry, Faculty of Science, M.S. University of Baroda, Baroda, 390 002 India.
Kumar K SinghAPI Division, Cadila Healthcare Limited, Sarkhej-Bavla N.H. No. 8 A, Changodar, Ahmedabad, 382 210 India.
Sameer AgarwalZydus Research Centre, Cadila Healthcare Ltd., Sarkhej-Bavla N.H. No. 8 A, Moraiya, Ahmedabad, 382 210 India.ORCID 0000-0002-7039-3028
Cadila Healthcare (India) · INMaharaja Sayajirao University of Baroda · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Forced degradation study is a systemic characterization of degradation products of active pharmaceutical ingredient (API) at conditions which posses more harsh environment that accelerates degradation of API. Forced degradation and stability studies would be useful in selection of proper, packaging material and storage conditions of the API. These are also useful to demonstrate degradation pathways and degradation products of the API and further characterisation of the degradation products using mass spectrometry. TGR5 is a G protein-coupled receptor, activation of which promotes secretion of glucagon-like peptide-1 (GLP-1) and modulates insulin secretion. The potent and orally bioavailable TGR5 agonist, ZY12201, shows activation of TGR5 which increase secretion of GLP-1 and help in lowering blood glucose level in animal models. Hence it is necessary to establish and study degradation pathway and stability of API for better handling and regulatory approval. Force degradation studies of ZY12201 have shown presence of one oxidative impurity during oxidative degradation in HPLC analysis. The oxidized product is further characterized by LC-MS to elucidate structure of impurity and characterize its degradation pathway. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s42452-021-04660-y.

Indexed as

Force degradation studyLC–MSOxidized productStress testingTGR5 agonist

Identifiers

PMID34056545
PMCPMC8144688
OpenAlexW3165666500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.